Neuro Hedge Capital is a research led investment entity created to monetise proprietary scientific alpha. It is built on sixteen years of privately funded research into neurodegeneration.

What has emerged is a confidential, asymmetric, and irreplaceable investment thesis rooted in biochemistry rather than models. It exposes structural flaws in the market narrative surrounding several public biotech companies. This work sits at the intersection of deep science and capital, offering a rare path to alpha that lies outside conventional pipelines.

With the support of a dedicated group of scientists and professors who remain behind the scenes, we have reached a level of clarity about Alzheimer’s disease, including its causes, mechanisms, trajectory, and viable cures, as well as related neurological conditions, that few thought possible. The scientific and market implications are evident to us, though not yet recognised by the market. The opportunities they present are significant and actionable.

The journey from empirical experimentation to molecular biochemistry reflects a consistent framework. We challenge assumptions by asking: what if everyone else is looking in the wrong place?

Our process is simple. The thesis is built on hard data, not gut feelings. We collect firsthand evidence, align it with biochemical mechanisms, and translate it into position timing and sizing.

Neuro Hedge Capital is now focused on structuring a vehicle that protects its informational edge while enabling aligned hedge fund partners to act decisively before the market catches up.